March 18, 2002

Ablation Revolutionizing Surgeries for Cancer, Gynecology, Prostate and Cardiac Arrhythmia

FOOTHILL RANCH, Calif. -- Tissue-altering surgical technologies, such as radiofrequency ablation, cryogenics, microwave and ultrasound, are improving treatment options for gynecological, urological, cardiac and cancer patients, among others, reports MedMarket Diligence in its March issue of “MedMarkets.”

“Exciting developments in surgical ablation technologies are fueling growth in several medical device sectors,” said Patrick J. Driscoll, publisher of “MedMarkets” and President of MedMarket Diligence.  “Ablation is being used to ablate unresectable tumors, to noninvasively treat uterine and breast cancer, to treat menorrhagia, and to refine benign prostatic hyperplasia,” he continued.  The market potential for products in these areas is great as the technology is still at the beginning of its growth curve.  For instance, the products market for unresectable liver tumors alone represents $500 million worldwide. 

In addition, competition is beginning to heat up as several devices now in clinical trials have just gained or have nearly gained FDA approval or clearance. Key companies involved in ablation cancer therapy include RITA Medical Systems and Radiotherapeutics; key companies involved in ablation of cardiac arrhythmias include Boston Scientific’s EP Technologies, Cardima, Medtronic, Bard Electrophysiology, Biosense Webster, Irvine Biomedical, Biotronik and Daig.

The March issue of “MedMarkets” also contains an article concerning recent advances in spinal surgery products, a market that is expected to grow in excess of 20% over the next decade due to advances in implantable devices.  Involved in this growing market are such key companies as:  ArthroCare, Radionics, DePuy, Stryker, Medtronic Sofamor Danek, Sulzer, Raymedica, SaluMedica, Link Spine Group, Aesculap, Interpore Cross and co.don, among others.

“MedMarkets” is a key monthly industry publication from MedMarket Diligence, LLC, that analyzes the market and clinical practice implications of developments in medical technology -- medical devices, equipment and supplies as well as biomaterials, biotech, pharmaceutical, e-health and others.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries.  In addition to “MedMarkets,” the company publishes dedicated market/technology reports, and is developing other information solutions.  For more information on “MedMarkets” or MedMarket Diligence, LLC, contact Patrick Driscoll at (949) 859-3401, e-mail, or visit the website at http://www.mediligence.com to view a sample issue in its entirety.

Contact: Patrick Driscoll, 949-859-3401